SEPN
HOLD / NEUTRALMeanRevComposite
43.50
Technical
95.40
Fundamental
26.20
Rank
—
Price
47.76
Hurst
0.28
As of
Aug 12, 2026
Daily
Septerna, Inc.
HealthcareBiotechnologySepterna is a clinical-stage biotech firm that develops oral small molecule treatments targeting G protein-coupled receptors for conditions in endocrinology, immunology, inflammation, and metabolic disease. The company's pipeline includes candidates for hypoparathyroidism, chronic spontaneous urticaria, and graves' disease, with additional programs in neurology, women's health, cardiovascular, and respiratory areas. Septerna has a global partnership with Novo Nordisk to research and develop oral therapies for metabolic diseases.
Market cap
$2.1B
P/E (trailing)
—
P/E (forward)
-22.67
PEG ratio
—
Dividend yield
0.00%
Beta
2.28
52w range
17.55 – 51.10
Return on equity
-6.34%
Profit margin
-24.51%
Revenue growth
+22375.60%
Earnings growth
—
Price history
1Y: 44.00 (+113.6%) · range 18.10–48.19
Cycle position
80/ 100 cycle scoreEXIT ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 3 · NOT READY · exit proximity 23
Conviction
9/ 100 · maturity 0%
Buildup.335
EMA entry setup.423
Fundamentals.2526
Volume profile
POC
37.06
Price vs POC
+18.7%
Overhead supply
9%
Runway
open sky
Value area 32.38–41.19 · 9% of 120d volume overhead · clean runway
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -21.66% | -6.33% | mature |
| 40d | -23.43% | -6.33% | mature |